HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Magdalini Matziari Selected Research

RXP03

2/2005Dosing and scheduling influence the antitumor efficacy of a phosphinic peptide inhibitor of matrix metalloproteinases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Magdalini Matziari Research Topics

Disease

3Neoplasms (Cancer)
01/2018 - 02/2005
1Human Influenza (Influenza)
01/2019
1Neoplasm Metastasis (Metastasis)
01/2018
1Carcinoma (Carcinomatosis)
02/2005

Drug/Important Bio-Agent (IBA)

2Matrix Metalloproteinase InhibitorsIBA
07/2007 - 02/2005
2Matrix Metalloproteinases (MMPs)IBA
07/2007 - 02/2005
1Antiparasitic Agents (Antiparasitics)IBA
01/2019
1Anti-Infective Agents (Microbicides)IBA
01/2019
1Antimalarials (Antimalarial Agents)IBA
01/2019
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
01/2018
1Peptides (Polypeptides)IBA
01/2018
1KisspeptinsIBA
01/2018
1RXP03IBA
02/2005
1Therapeutic UsesIBA
02/2005